Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
19
BBC Quote, Financials, Valuation and Earnings
Last price:
$19.58
Seasonality move
:
0.69%
Day range:
$19.71 - $20.22
52-week range:
$18.77 - $31.65
Dividend yield:
1.2%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
333.1K
Avg. volume:
23K
1-year change:
-31.61%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$19.98 | -- | -- | -- | $0.24 | 1.2% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$10.74 | -- | -- | -- | $0.00 | 0% | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$16.22 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$65.72 | -- | -- | -- | $0.01 | 0.05% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$83.50 | -- | -- | -- | $0.03 | 0.04% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.069 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.328 | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.696 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.203 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.687 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About BBC or CNCR?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is BBC or CNCR More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, which suggesting that the stock is 7.979% more volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.282%.
-
Which is a Better Dividend Stock BBC or CNCR?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.2%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or CNCR?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns BBC or EKG?
First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -
What do Analysts Say About BBC or EKG?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 -
Is BBC or EKG More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, which suggesting that the stock is 7.979% more volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BBC or EKG?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.2%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or EKG?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- --
-
Which has Higher Returns BBC or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBC or PBE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, which suggesting that the stock is 7.979% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.832, suggesting its less volatile than the S&P 500 by 16.774%.
-
Which is a Better Dividend Stock BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.2%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBC or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is BBC or XHE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, which suggesting that the stock is 7.979% more volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.054, suggesting its more volatile than the S&P 500 by 5.419%.
-
Which is a Better Dividend Stock BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.2%. SPDR S&P Health Care Equipment ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 21
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 1.11% over the past day.
Sell
15
FG alert for Mar 21
F&G Annuities & Life [FG] is down 4.61% over the past day.
